Therefore, we employed the biological PET staging of AD, recently proposed by the Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease (2024)10 and aimed to assess the ability of plasma p217+tau using the widely available Simoa® platform to discriminate individuals that fall within these stages. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.